Nanjing Youmai Biological Technology

Nanjing Youmai Biological Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic disorders, such as type 2 diabetes, and oncology. Its lead program, UM-001, is a potent GPR119 agonist designed to improve glycemic control and lipid metabolism, currently undergoing Phase 1 clinical trials. Nanjing Youmai leverages its internal R&D capabilities to advance a pipeline of candidates aimed at addressing significant unmet medical needs. The company is situated in the Nanjing Jiangbei New Area, a hub for biotechnology innovation.